

Does allopurinol/urate lowering by xanthine oxidase inhibition have an impact on arterial stiffness in stroke survivors?

Submission date 29/11/2006	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 13/12/2006	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 24/03/2011	Condition category Circulatory System	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Faisel Khan

Contact details
Department of Vascular Medicine
Level 7
Ninewells Hospital
Dundee
United Kingdom
DD1 9SY
+44 (0)1382 635574
f.khan@dundee.ac.uk

Additional identifiers

Protocol serial number
Res 02/ A60 2464/02/05

Study information

Scientific Title

Study objectives

After the first year of an ischaemic cerebrovascular event (stroke), cardiovascular disease becomes the most common cause of death. A growing body of evidence suggests that serum uric acid is an independent marker of cardiovascular risk. We have shown previously that high urate is associated with cardiac death in 354 stroke survivors who were followed up for a median of 2.8 years, independently of conventional risk factors for atherosclerosis, creatinine and diuretic use.

A larger study by Weir et. al., confirmed these findings and showed that higher serum urate levels, measured on admission to hospital, predicted poor outcome and higher future vascular events after acute stroke.

We sought therefore to determine how uric acid levels correlate with arterial stiffness in those who have cardiovascular disease i.e. stroke survivors. Additionally, several studies have shown that allopurinol improves endothelial function, but its effect on arterial stiffness is not known and finding this out was our second aim.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethical approval for the study was obtained from the local ethics committee (Tayside Medical Ethics Committee, Scotland) and all subjects gave written, informed consent. All study related procedures were conducted according to institutional guidelines and the Declaration of Helsinki.

Study design

Randomised, double blinded , placebo controlled study

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Stroke

Interventions

Patients were randomly allocated to receive either allopurinol 300 mg once daily or matched placebo. Baseline measurements were taken as part of the initial study and follow-up measurements were made after eight weeks of treatment.

Patients attended for one additional visit at two weeks, non-fasted, for measurements of urea and electrolytes, liver function testing, and for monitoring of any adverse reactions.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Allopurinol

Primary outcome(s)

Correlation between arterial stiffness and urate levels.

Key secondary outcome(s))

Effect of allopurinol on arterial stiffness.

Completion date

01/04/2003

Eligibility

Key inclusion criteria

Stroke survivors who have a high serum urate

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Not Specified

Sex

Key exclusion criteria

1. Documented reaction to allopurinol
2. Persons who were incapable of giving informed consent

Date of first enrolment

01/02/2002

Date of final enrolment

01/04/2003

Locations

Countries of recruitment

United Kingdom

Scotland

Study participating centre

Department of Vascular Medicine
Dundee
United Kingdom
DD1 9SY

Sponsor information

Organisation

University of Dundee (UK)

ROR

<https://ror.org/03h2bxq36>

Funder(s)

Funder type

Charity

Funder Name

Chest Heart and Stroke Scotland (Grant Ref: Res 02/ A60)

Funder Name

Heart Research UK (Grant Ref 2464/02/05)

Alternative Name(s)

HRUK

Funding Body Type

Private sector organisation

Funding Body Subtype

Trusts, charities, foundations (both public and private)

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/11/2008		Yes	No